AR051350A1 - Vacuna de glucoproteina mucinosa (muc-1) - Google Patents

Vacuna de glucoproteina mucinosa (muc-1)

Info

Publication number
AR051350A1
AR051350A1 ARP050101311A ARP050101311A AR051350A1 AR 051350 A1 AR051350 A1 AR 051350A1 AR P050101311 A ARP050101311 A AR P050101311A AR P050101311 A ARP050101311 A AR P050101311A AR 051350 A1 AR051350 A1 AR 051350A1
Authority
AR
Argentina
Prior art keywords
muc
subject
amino acid
acid sequence
formulation
Prior art date
Application number
ARP050101311A
Other languages
English (en)
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of AR051350A1 publication Critical patent/AR051350A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método de tratamiento de un sujeto que sufre de cáncer, tal como cáncer de pulmon de células no pequenas o cáncer e prostata, que comprende administrarle a dicho sujeto una formulacion basada en MUC-1. La formulacion puede ser una vacuna liposomica basada en la formulacion MUC-1. Reivindicacion 1: Un método de tratamiento de un sujeto con cáncer de pulmon de células no pequenas, caracterizado porque comprende: (a) seleccionar para el tratamiento un sujeto que sufre e cáncer de pulmon de células no pequenas, y (b) administrarle a dicho sujeto, por un período de tiempo, una formulacion basada en MUC-1, donde dicha formulacion comprende un liposoma que contiene al menos un polipéptido que comprende la secuencia de aminoácidos seleccionada del grupo formado por la secuencia de aminoácidos de la SEQ ID N.:1, una variante de la secuencia de aminoácidos de la SEQ ID N.:1, la secuencia de aminoácidos de la SEQ ID N.:2 y una variante de la secuencia de aminoácidos de la SEQ ID N.:2.
ARP050101311A 2004-04-01 2005-04-01 Vacuna de glucoproteina mucinosa (muc-1) AR051350A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55813904P 2004-04-01 2004-04-01
US57680404P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
AR051350A1 true AR051350A1 (es) 2007-01-10

Family

ID=35428714

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101311A AR051350A1 (es) 2004-04-01 2005-04-01 Vacuna de glucoproteina mucinosa (muc-1)

Country Status (16)

Country Link
US (2) US9173929B2 (es)
EP (2) EP1737485B1 (es)
JP (3) JP5590768B2 (es)
CN (2) CN103933556A (es)
AR (1) AR051350A1 (es)
AU (1) AU2005244675B2 (es)
BR (1) BRPI0509552A (es)
CA (1) CA2562990A1 (es)
DK (2) DK2524700T3 (es)
ES (2) ES2478006T3 (es)
HK (1) HK1109574A1 (es)
HU (1) HUE027378T2 (es)
PL (2) PL1737485T3 (es)
PT (2) PT1737485E (es)
TW (2) TW201204410A (es)
WO (1) WO2005112546A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE343375T1 (de) 2001-03-27 2006-11-15 Biomira Inc Impfstoff zur modulation zwischen t1 und t2 immunantworten
JP4527407B2 (ja) * 2002-04-15 2010-08-18 オンコサイレオン インコーポレーテッド ワクチンとしての合成グリコリポペプチド
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
US8871250B2 (en) * 2005-06-28 2014-10-28 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
AU2012268892B2 (en) * 2005-06-28 2016-05-26 Oncothyreon Inc. Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
US20120034294A1 (en) * 2008-12-17 2012-02-09 Oncothyreon, Inc. Method of making small liposomes
WO2011054359A2 (en) * 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
EP2560989B1 (en) 2010-04-19 2017-03-22 Sumitomo Bakelite Co., Ltd. Cancer-related glycopeptide epitopes, antibodies and methods of use
CN105193724A (zh) * 2011-02-24 2015-12-30 肿瘤防护公司 含有佐剂的以muc1 为基础的糖脂肽疫苗
EP4052721A1 (en) 2011-06-24 2022-09-07 NoNO Inc. Combination therapy for ischemia
DE102011085695A1 (de) * 2011-11-03 2013-05-08 Jörg Pohl Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
SG11201509357WA (en) 2013-05-14 2015-12-30 Merck Patent Gmbh Method of treating lung cancer by vaccination with muc-1 lipopeptide
KR20160043103A (ko) * 2013-08-21 2016-04-20 큐어백 아게 전립선암 치료를 위한 조성물 및 백신
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
CN110393797A (zh) * 2019-05-27 2019-11-01 南开大学 基于糖脂佐剂的糖肽疫苗的制备方法与应用
WO2022125956A1 (en) * 2020-12-11 2022-06-16 Trustees Of Boston University Immunomodulatory lipopolysaccharide compositions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
DE3683688D1 (de) 1985-04-19 1992-03-12 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
ATE136211T1 (de) 1989-06-23 1996-04-15 Liposome Co Inc Zielliposomen und verfahren zur kupplung von liposomen-proteinen
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
WO1995027505A1 (en) 1994-04-12 1995-10-19 Biomira, Inc. Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1996040236A1 (en) 1995-06-07 1996-12-19 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecules and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
CA2249395A1 (en) * 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
CA2252055C (en) 1996-04-11 2007-01-16 The University Of British Columbia Fusogenic liposomes
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
EP2341072A3 (en) 1997-05-08 2013-10-30 Oncothyreon Inc. Method for Generating Activated T-Cells and Antigen-Pulsed Antigen-Presenting Cells
JPH11139961A (ja) 1997-11-06 1999-05-25 Taisho Pharmaceut Co Ltd リポソームの製造方法
EP1045688A1 (en) 1998-01-16 2000-10-25 Biomira Usa Inc. Lipomatrix preparation
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US6104536A (en) 1998-09-18 2000-08-15 3M Innovative Properties Company High efficiency polarization converter including input and output lenslet arrays
WO2000029103A1 (en) 1998-11-13 2000-05-25 Optime Therapeutics, Inc. Method and apparatus for liposome production
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001012217A1 (en) 1999-08-18 2001-02-22 Altarex Corp. Therapeutic antibody against muc-1 antigen and methods for their use
ATE338121T1 (de) 1999-09-08 2006-09-15 Transgene Sa Von muc-1 abgeleitete peptide
AU780577B2 (en) 1999-11-15 2005-04-07 Oncothyreon Inc. Synthetic Lipid-A analogs and uses thereof
AU4871001A (en) 2000-03-24 2001-10-03 Biomira Inc Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
WO2002043699A2 (en) * 2000-12-01 2002-06-06 Biomira, Inc. Preparation of large liposomes by infusion into peg
ATE343375T1 (de) 2001-03-27 2006-11-15 Biomira Inc Impfstoff zur modulation zwischen t1 und t2 immunantworten
EP1458242A4 (en) * 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
JP3760467B2 (ja) 2002-04-09 2006-03-29 ソニー株式会社 コンテンツ再生装置および方法、記録媒体、並びにプログラム
JP4527407B2 (ja) 2002-04-15 2010-08-18 オンコサイレオン インコーポレーテッド ワクチンとしての合成グリコリポペプチド
CA2485253C (en) 2002-05-09 2012-07-10 Biomira, Inc. Lipid a and other carbohydrate ligand analogs
US20030235610A1 (en) 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
WO2004071638A2 (en) 2003-02-11 2004-08-26 Regents Of The University Of California, The Microfluidic devices and method for controlled viscous shearing and formation of amphiphilic vesicles
US9198645B2 (en) 2003-11-26 2015-12-01 The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology Controlled vesicle self-assembly in continuous two phase flow microfluidic channels
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
US8871250B2 (en) 2005-06-28 2014-10-28 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
JP5126874B2 (ja) 2007-05-21 2013-01-23 国立大学法人神戸大学 リポソーム製剤の製造方法
US20120034294A1 (en) 2008-12-17 2012-02-09 Oncothyreon, Inc. Method of making small liposomes

Also Published As

Publication number Publication date
EP1737485B1 (en) 2014-05-07
TWI395591B (zh) 2013-05-11
AU2005244675A1 (en) 2005-12-01
HUE027378T2 (en) 2016-10-28
PT1737485E (pt) 2014-08-22
JP5868125B2 (ja) 2016-02-24
EP1737485A2 (en) 2007-01-03
PL1737485T3 (pl) 2014-10-31
ES2478006T3 (es) 2014-07-18
CN1997388B (zh) 2014-03-26
CN103933556A (zh) 2014-07-23
ES2560808T3 (es) 2016-02-22
WO2005112546A2 (en) 2005-12-01
US20080131495A1 (en) 2008-06-05
US20160082093A1 (en) 2016-03-24
EP1737485A4 (en) 2008-09-03
DK1737485T3 (da) 2014-08-04
US9173929B2 (en) 2015-11-03
DK2524700T3 (en) 2016-02-01
BRPI0509552A (pt) 2007-09-18
HK1109574A1 (en) 2008-06-13
PL2524700T3 (pl) 2016-04-29
JP2014177479A (ja) 2014-09-25
TW200538147A (en) 2005-12-01
EP2524700B1 (en) 2015-10-28
JP2007530663A (ja) 2007-11-01
EP2524700A1 (en) 2012-11-21
AU2005244675B2 (en) 2011-07-21
CA2562990A1 (en) 2005-12-01
TW201204410A (en) 2012-02-01
JP2012092105A (ja) 2012-05-17
PT2524700E (pt) 2016-02-29
JP5590768B2 (ja) 2014-09-17
WO2005112546A3 (en) 2006-05-04
CN1997388A (zh) 2007-07-11

Similar Documents

Publication Publication Date Title
AR051350A1 (es) Vacuna de glucoproteina mucinosa (muc-1)
AR054526A1 (es) Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)
ES2542853T3 (es) Método para tratar miastenia grave
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
ES2668926T3 (es) Composición de ARN para el tratamiento del cáncer pulmonar de células no pequeñas (NSCLC)
EP2679246A3 (en) Novel therapeutical tools and methods for treating blindness
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
AR036160A1 (es) Regulacion de las vias metabolicas lipidicas en las plantas, mediante transgenesis con sentido o antisentido de factores de transcripcion hap2, hap5 y hap3/lec1
SI1675954T1 (sl) Nukleinske kisline uporabne za sproĺ˝anje letalnosti tumorske celice
HK1124077A1 (en) Kdr peptides and vaccines comprising the same
NZ620441A (en) Pcsk9 vaccine
WO2010060104A3 (en) Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
PE20191529A1 (es) Peptidos y metodos para el tratamiento de diabetes
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
TW200507840A (en) Method of treating multiple myeloma
WO2009108706A3 (en) Methods for inhibiting six 1 and eya proteins
WO2007103876A8 (en) Cancer therapeutic
UA94231C2 (ru) Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
GB201105584D0 (en) Cancer methods
ES2421407T3 (es) Agente y composición para la curación de heridas
MX2010010177A (es) Fragmentos de beta timosina mejorada.
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2007014199A3 (en) Tfpi fragments as anti-microbial agents

Legal Events

Date Code Title Description
FC Refusal